Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disea
β¦ LIBER β¦
Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study
β Scribed by John D. Cowan; Stephanie Green; Joel Lucas; James K. Weick; Stanley P. Balcerzak; Saul E. Rivkin; Charles A. Coltman; Laurence H. Baker
- Publisher
- Springer US
- Year
- 1988
- Tongue
- English
- Weight
- 116 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A phase II evaluation of cisplatin in un
β
Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balc
π
Article
π
1988
π
Springer US
π
English
β 240 KB
A phase II evaluation of ifosfamide and
β
Bernard L. Zidar; Barbara Metch; Stanley P. Balcerzak; H. Irving Pierce; Liboria
π
Article
π
1992
π
John Wiley and Sons
π
English
β 531 KB
A phase II trial of paclitaxel in patien
β
Stanley P. Balcerzak; Jacqueline Benedetti; Geoffrey R. Weiss; Ronald B. Natale
π
Article
π
1995
π
John Wiley and Sons
π
English
β 461 KB
π 3 views
A phase II trial of combination chemothe
β
Ronald M. Bukowski; Katherine G. Johnson; Robert F. Peterson; Ronald L. Stephens
π
Article
π
1987
π
John Wiley and Sons
π
English
β 504 KB
Phase II study of aziridinylbenzoquinone
β
Sarah A Taylor; Joseph D McCracken; Harmon J Eyre; Robert M O'Bryan; Barbara A N
π
Article
π
1985
π
Springer US
π
English
β 314 KB
A Phase II trial of vinorelbine tartrate
β
Robert P. Whitehead; James Moon; S. Spence McCachren; Evan M. Hersh; Wolfram E.
π
Article
π
2004
π
John Wiley and Sons
π
English
β 84 KB
π 3 views
## Abstract ## BACKGROUND Singleβagent chemotherapy with dacarbazine continues to be the standard of care for the treatment of metastatic melanoma. However, there is a large population of patients who have failed firstβline therapy and might benefit from additional treatment. In the current study,